Apollo Hospitals Enterprise Ltd.
Snapshot View

4075.50 +8.20 ▲0.2%

05 August 2021, 04:00:00 P.M.
Volume: 7,162

Overview View Details

Sector Healthcare Compare with Sector peers
Industry Hospital & Healthcare Services Compare with Industry peers
Website http://www.apollohospitals.com
Financial Indicators
Market Cap 58,599.44 Cr.
Earnings per share (EPS) 10.46 Trailing Twelve Months Ending 2021-03
Price-Earning Ratio (PE) 389.73 Trailing Twelve Months Ending 2021-03
Industry PE 202.10 Trailing Twelve Months Ending 2021-03
Book Value / Share 319.56 Trailing Twelve Months Ending 2021-03
Price to Book Value 12.75 Calculated using Price: 4,075.50
Dividend Yield 0.07 Period Ending 2020-03
No. of Shares Subscribed 14.38 Cr. 143,784,657 Shares
FaceValue 5
Company Profile

Apollo Hospitals Enterprise was established in 1983, renowned as the architect of modern healthcare in India. As the nation’s first corporate hospital, it is acclaimed for pioneering the private healthcare revolution in the country. The cornerstones of Apollo’s legacy are its unstinting focus on clinical excellence, affordable costs, modern technology and forward-looking research & academics. It was among the first few hospitals in the world to leverage technology to facilitate seamless healthcare delivery. The organization embraced the rapid advancement in medical equipments across the world, and pioneered the introduction of several cutting edge innovations in India.  Apollo Hospitals has championed numerous social initiatives - to cite a few which assist underprivileged children - SACHi (Save a Child's Heart Initiative) which screens and provides paediatric cardiac care for congenital heart diseases, SAHI (Society to Aid the Hearing Impaired) and the CURE Foundation focused on cancer care.

Business area of the company

The company has emerged as Asia’s foremost integrated healthcare services provider and has a robust presence across the healthcare ecosystem, including Hospitals, Pharmacies, Primary Care & Diagnostic Clinics and several retail health models. The Group also has Telemedicine facilities across several countries, Health Insurance Services, Global Projects Consultancy, Medical Colleges, Medvarsity for E-Learning, Colleges of Nursing and Hospital Management and a Research Foundation. In addition, ‘ASK Apollo’ - an online consultation portal and Apollo Home Health provide the care continuum.

Services offered by the company:

  • Cardiology & Cardiothoracic Surgery
  • Orthopedics & Joint Replacement Surgery
  • Spine Surgery
  • Oncology
  • Medical & Surgical Gastroenterology
  • Neurology & Neurosurgery
  • Nephrology & Urology
  • Critical Care Medicine

Medical Milestones:

  • Touched over 42 Million lives and still counting.
  • Performed over 20 Million Preventive Health Checks so far.
  • 1 Million minor surgical procedures performed.
  • 7,50,000 major surgeries performed and counting.
  • Crossed over 1,50,000 Heart Surgeries with incredible success rates.
  • 1,25,000 Coronary Angioplasties done till 2013.
  • Completed over 10,000 Joint Replacement Surgeries.
  • 10,000 Neurosurgeries performed per year.
  • First program to complete over 15000 Kidney transplants.
  • Apollo Speciality Cancer Hospital, Chennai successfully completes 1500 CyberKnife Radio Surgeries.
  • Over 1500 solid organ transplants were performed in a year.
  • Apollo Speciality Cancer Hospital, Chennai successfully completes 1500 CyberKnife Radio Surgeries.
  • 1000 patients successfully treated through exultant Micro vascular free tissue transfer and Aesthetic surgeries.
  • First program to complete over 3500 Liver transplants.
  • Over 1500 Bone Marrow Transplants.
  • Apollo Health City has performed 1500 Cochlear implant surgery and reached a new milestone in the history of aiding hearing impaired in Andhra Pradesh.
  • 375 liver transplants performed by Apollo Hospitals, Chennai and Delhi.
  • 345 liver transplantations at Apollo Chennai's Center for Liver Disease.
  • Countries Medical Value Travel.
  • 25 World Class Heart Institutes.
  • 25 NABH (National Accreditation Board for Hospitals) accredited hospitals.
  • 8 JCIA accredited hospitals.
  • 6 centres in India on global trial for drug-eluting bio-resorb able stents. Apollo is one of them.

Achievements/Milestones

  • Apollo Hospitals, Chennai successfully performs Asia's first en-bloc combined heart & liver transplant, joining a very small set of transplant centers in the world to have done this.
  • Apollo Hospitals, Hyderabad successfully treats a critically ill eleven day old baby with a complex and rare cardiac surgery - a first of its kind in India.
  • Apollo Hospitals, Chennai introduces 'the Ideal Knee' - the future of Total Knee Replacement through a new technique - Attune Rotating Platform Knee Replacement, a first of its kind in South India.
  • Apollo Health City, Hyderabad performed the First bilateral (on both the knees) revolutionary Minimally Invasive Knee Replacement (Resurface) Surgery (MIKRS) using OrthoGlide Medial Knee system.
  • Apollo Hospitals, Chennai successfully performed a Robotic surgery for Cancer base of the tongue, a first of its kind in Tamil Nadu.
  • Thoraco Omphalopagus conjoined female twins from Tanzania were successfully separated at Apollo Children's Hospital.
  • Pioneered open heart surgeries and cardiac catheterization, in the early 80's.
  • First private healthcare provider to perform a heart transplant in 1995.
  • By 1992, Apollo Hospitals introduced Artery Stenting for the first time in India.
  • Indraprastha Apollo Hospitals, Delhi completed over 500 liver transplants in February, 2011.
  • In 1995, Apollo Hospitals performed its first Bone Marrow Transplantation, as well as the first multi organ transplant in the country.
  • Pediatric Surgeons at Apollo Children's Hospital Chennai evolved their own standardized techniques for valve repair, April to June 2012.
  • Apollo Hospitals, Hyderabad performed the first coronary angioplasty in India using absorb fully absorbable stent-bioresorbable vascular scaffold (absorb-BVS) - 2012.
  • Apollo Health City Hyderabad commenced Robotic Procedures during April to June 2012, in the specialities of Gynecology & Urology.
  • Indraprastha Apollo Hospitals New Delhi commenced Robotic Surgery in the specialities of Gynecology, Urology, General Surgery and Bariatric Surgery, during April to June 2012.
  • Apollo Gleneagles Cancer Hospital launched Eastern India's first dedicated comprehensive Bone Marrow Transplant Unit.
  • Apollo Hospitals, Chennai performed a double-lung transplantation for Hermansky-Pudlak Syndrome (HPS) genetic condition which was the first case in India and second in the world. HPS results from mutations in one of seven different genes.
  • Apollo performed an unprecedented revolution in orthopedics by equalizing limbs and deformity correction by the llizarov procedure.
  • An 8 year old Omani child with aortoarteritis, uncontrollable hypertension with impending kidney failure and intestinal gangrene was successfully treated by vascular reconstructive surgery at Apollo hospitals Chennai.
  • World's 1st iPod Navigation Hip Resurfacing Surgery was successfully performed at Apollo Speciality Hospitals, Chennai.
  • Latest M guard stent technology, a specially designed Mesh covered stent, was used to save a 27 year old man from an acute heart attack, Apollo Hospital first to introduce the technology in Chennai.
  • First American underwent a successful Heart Transplant at Chennai's Apollo Hospitals and he was also the oldest person to undergo a heart transplant in the country.
  • Apollo Bramwell Hospital Mauritius in conjunction with Global Biohealth Solutions, launched the Apollo Bramwell Stem Cell Therapy Program.
  • Introduced cutting edge procedures like off-pump and beating-heart surgery, either by thoracotomy or classical sternotomy, trans-radial angioplasty and stenting, mitral valve replacement.
  • First donor incompatible kidney transplant performed at Apollo Hospitals Chennai using technique of Column adsorption of blood group antibodies.
  • Stealth Surgery, a subcutaneous endoscopic surgery which addresses concerns related to scarring was performed at Apollo Children's Hospital, Chennai.
  • Largest series of aortic valve replacement with stentless heart valve bioprosthesis performed.
  • Apollo Hospitals, Chennai successfully performed the first simultaneous Liver-Intestine-Pancreas transplant in India.
  • Apollo Hospitals, Chennai successfully performed a combined heart and lung transplant on the oldest recorded recipient in India.
  • Apollo Hospitals, Chennai completes the highest number of Combined Heart and Double Lung Transplants in India.
  • India's first Total Marrow Irradiation Procedure was performed on a 35-year-old patient from Oman by Apollo Proton Cancer Centre, Chennai.
  • India's first successful combined cardiac and tracheal surgery was performed on 11-month-old baby from Oman by Apollo Children's Hospital, Chennai.
  • Asia's first simultaneous Kidney-Pancreas Transplant was performed on a 38-year-old patient by Apollo Hospitals, Chennai.
  • Apollo Hospitals, Chennai successfully performed over 50,000 cardiac surgeries which includes Bypass, Valve replacements, Pediatric cardiac procedures, Transplants and Minimally invasive procedures.
  • The first ever Transfemoral Pulmonary Valve Implantation using an Indian-made valve, MYVAL, was performed by Apollo Hospitals, Chennai.

Delivery View Details

Delivered Qty
Traded Qty

Performance View Details

1 Day
+0.20%
1 Week
+0.92%
1 Month
+9.57%
3 Month
+22.15%
6 Month
+48.73%
1 Year
+143.20%
2 Year
+213.32%
5 Year
+199.49%
9 years 2012-03 2013-03 2014-03 2015-03 2016-03 2017-03 2018-03 2019-03 2020-03
Return on Equity (%) 9.82 11.28 10.66 10.59 6.41 2.68 1.81 6.07 13.08
Return on Capital Employed (%) 13.43 13.79 12.71 12.09 8.57 6.94 7.12 10.24 17.13
Return on Assets (%) 5.56 6.69 6.00 5.51 3.01 1.10 0.65 2.05 3.90

Balance Sheet View Details

Particulars 9 years 2012-03 Rs. Cr. 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr.
Shh. Funds 2,507 2,747 2,977 3,171 3,331 3,313 3,252 3,334 3,339
Non Curr. Liab. 737 1,316 1,557 2,138 2,701 4,399 4,423 4,613 6,483
Curr. Liab. 726 734 797 1,076 1,250 963 1,567 1,955 2,337
Minority Int. 13 17 19 73 78 125 132 136 131
Equity & Liab. 3,983 4,814 5,350 6,459 7,360 8,800 9,374 10,037 12,290
Non Curr. Assets 2,920 3,261 3,849 4,520 5,385 6,671 7,154 7,756 9,643
Curr. Assets 1,062 1,553 1,501 1,939 1,975 2,129 2,220 2,282 2,647
Misc. Exp. not W/O
Total Assets 3,983 4,814 5,350 6,459 7,360 8,800 9,374 10,037 12,290

Profit Loss View Details

Particulars 9 years 2012-03 Rs. Cr. 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr.
Net Sales 3,148 3,769 4,384 5,178 6,215 7,256 8,243 9,617 11,247
Other Income 26 30 21 37 53 44 34 32 33
Total Income 3,173 3,799 4,406 5,215 6,267 7,300 8,277 9,650 11,280
Total Expenditure -2,634 -3,161 -3,712 -4,444 -5,534 -6,549 -7,452 -8,555 -9,666
PBIDT 539 638 694 771 733 751 825 1,095 1,614
Interest -89 -103 -119 -118 -180 -257 -295 -327 -533
Depreciation -124 -142 -168 -212 -264 -314 -359 -396 -620
Taxation -115 -105 -102 -130 -97 -91 -112 -173 -225
Exceptional Items 6 13 16 199
PAT 211 294 305 325 208 89 59 199 435

Cash Flow View Details

Particulars 9 years 2012-03 Rs. Cr. 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr.
Cash Fr. Operatn. 387 443 373 470 597 623 537 905 1,293
Cash Fr. Inv. -468 -733 -356 -759 -888 -1,152 -405 -711 -289
Cash Fr. Finan. 135 373 -63 392 330 477 -109 -215 -910
Net Change 54 83 -46 103 39 -52 24 -20 95
Cash & Cash Eqvt 237 320 274 377 379 283 306 286 381

Shareholding Pattern View Details

9 Qtrs 2019-06 (%) 2019-09 (%) 2019-12 (%) 2020-03 (%) 2020-06 (%) 2020-09 (%) 2020-12 (%) 2021-03 (%) 2021-06 (%)
Promoter 34.40 30.80 30.80 30.81 30.82 30.82 30.82 29.82 29.82
Public 65.60 69.11 69.20 69.16 69.18 69.18 69.08 70.18 70.12
Depository Receipts 0.09 0.09 0.00 0.03 0.05 0.00 0.10 0.00 0.06
Promoter Holding Pledge (%) 71.26 66.19 67.33 36.66 36.65 33.65 30.14 27.94 29.95

Announcements View Details

Wed, 04 Aug 2021
Board Meeting Intimation for Notice Of The Board Meeting
APOLLO HOSPITALS ENTERPRISE LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/08/2021 inter alia to consider and approve As per annexure enclosed
Wed, 28 Jul 2021
Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 for Sands Capital Management LLC
Wed, 21 Jul 2021
Annual General Meeting Scheduled To Be Held On 31St August 2021
as per annexure enclosed

Technical Scans View Details

Wed, 04 Aug 2021
Close Within 52 Week High Zone Close Within 52 Week High Zone
CCI Bearish CCI Bearish
RSI Overbought Zone RSI Overbought Zone
MFI Above 80 MFI Above 80
Tue, 03 Aug 2021
Higher Trade Quantity Higher Trade Quantity

Related Stocks View Details

Stock Name Market Cap(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. 188,527.75 785.85 +0.0%
Divi's Laboratories Ltd. 131,785.24 4,923.45 -0.9%
Dr. Reddy's Laboratories Ltd. 79,333.82 4,783.30 +0.2%
Cipla Ltd. 75,796.16 945.20 +0.6%
Cadila Healthcare Ltd. 60,170.47 584.80 -0.5%
Piramal Enterprises Ltd. 57,915.28 2,601.15 +2.0%
Aurobindo Pharma Ltd. 53,118.26 908.65 +0.3%
Stock Name Statement TTM Ending Price Earning Ratio(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-06 31.40 785.85 +0.0%
Divi's Laboratories Ltd. Consolidated 2021-03 66.41 4,923.45 -0.9%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-06 45.66 4,783.30 +0.2%
Cipla Ltd. Consolidated 2021-03 31.52 945.20 +0.6%
Cadila Healthcare Ltd. Consolidated 2021-03 28.20 584.80 -0.5%
Piramal Enterprises Ltd. Consolidated 2021-03 43.47 2,601.15 +2.0%
Aurobindo Pharma Ltd. Consolidated 2021-03 9.96 908.65 +0.3%
Stock Name Statement TTM Ending Price To Book Value(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-06 3.94 785.85 +0.0%
Divi's Laboratories Ltd. Consolidated 2021-03 14.18 4,923.45 -0.9%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-06 4.44 4,783.30 +0.2%
Cipla Ltd. Consolidated 2021-03 4.15 945.20 +0.6%
Cadila Healthcare Ltd. Consolidated 2021-03 4.63 584.80 -0.5%
Piramal Enterprises Ltd. Consolidated 2021-03 1.69 2,601.15 +2.0%
Aurobindo Pharma Ltd. Consolidated 2021-03 2.42 908.65 +0.3%
Stock Name Statement Year Ending Debt Equity Ratio LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 0.18 785.85 +0.0%
Divi's Laboratories Ltd. Consolidated 2020-03 0.00 4,923.45 -0.9%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 0.17 4,783.30 +0.2%
Cipla Ltd. Consolidated 2021-03 0.10 945.20 +0.6%
Cadila Healthcare Ltd. Consolidated 2021-03 0.35 584.80 -0.5%
Piramal Enterprises Ltd. Consolidated 2021-03 1.16 2,601.15 +2.0%
Aurobindo Pharma Ltd. Consolidated 2020-03 0.33 908.65 +0.3%
Stock Name Statement Year Ending Return On Equity(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 9.66 785.85 +0.0%
Divi's Laboratories Ltd. Consolidated 2020-03 19.30 4,923.45 -0.9%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 11.53 4,783.30 +0.2%
Cipla Ltd. Consolidated 2021-03 14.13 945.20 +0.6%
Cadila Healthcare Ltd. Consolidated 2021-03 18.30 584.80 -0.5%
Piramal Enterprises Ltd. Consolidated 2021-03 3.33 2,601.15 +2.0%
Aurobindo Pharma Ltd. Consolidated 2020-03 18.53 908.65 +0.3%
Stock Name Statement Year Ending Return On Capital Employed(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 10.07 785.85 +0.0%
Divi's Laboratories Ltd. Consolidated 2020-03 25.36 4,923.45 -0.9%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 15.24 4,783.30 +0.2%
Cipla Ltd. Consolidated 2021-03 17.85 945.20 +0.6%
Cadila Healthcare Ltd. Consolidated 2021-03 13.65 584.80 -0.5%
Piramal Enterprises Ltd. Consolidated 2021-03 10.03 2,601.15 +2.0%
Aurobindo Pharma Ltd. Consolidated 2020-03 18.80 908.65 +0.3%
Stock Name Statement Year Ending Net Sales(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 32,837.50 785.85 +0.0%
Divi's Laboratories Ltd. Consolidated 2020-03 6,969.40 4,923.45 -0.9%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 19,047.50 4,783.30 +0.2%
Cipla Ltd. Consolidated 2021-03 19,159.59 945.20 +0.6%
Cadila Healthcare Ltd. Consolidated 2021-03 15,102.20 584.80 -0.5%
Piramal Enterprises Ltd. Consolidated 2021-03 12,809.35 2,601.15 +2.0%
Aurobindo Pharma Ltd. Consolidated 2020-03 23,098.51 908.65 +0.3%
Stock Name Statement Year Ending Profit After Tax(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 4,186.79 785.85 +0.0%
Divi's Laboratories Ltd. Consolidated 2020-03 1,984.29 4,923.45 -0.9%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 1,903.60 4,783.30 +0.2%
Cipla Ltd. Consolidated 2021-03 2,401.30 945.20 +0.6%
Cadila Healthcare Ltd. Consolidated 2021-03 2,137.60 584.80 -0.5%
Piramal Enterprises Ltd. Consolidated 2021-03 1,074.43 2,601.15 +2.0%
Aurobindo Pharma Ltd. Consolidated 2020-03 2,844.69 908.65 +0.3%